Mirjam Keßler, Wolfgang Rottbauer, Jochen Wöhrle
In addition to traditional chemotherapeutic regimens molecular targeted agents emerged as new therapeutic options for the treatment of non-small-cell lung cancer (NSCLC).
These targeted therapies do not have the same systemic adverse effects usually observed with traditional cytotoxic drugs, but feature a specific spectrum of characteristic adverse effects.
The humanized monoclonal antibody against the VEGF-A ligand Bevacizumab inhibits angiogenesis. The characteristic toxicities of Bevacizumab include hemorrhage, wound healing complications, gastrointestinal perforation, arterial thromboembolism, and infusion-related hypersensitivity reactions.
We present a unique case of a left ventricular wall perforation after myocardial infarction associated with the administration of Bevacizumab in NSCLC. Cardiac MRI follow-up showed regression of the ventricular perforation.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu